All In Biotech

Drug Trial Radar · NCT07221500

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Oct 15, 2025

Primary completion

Jan 2028

Study completion Oct 2030

Sponsor

Lead sponsor
Nurix Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexobrutideg) works to treat patients with CLL/SLL. Participation could last up to 5 years, and possibly longer, if the disease does not progress.

Conditions

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)

Interventions

  • NX-5948Drug

    Oral dose administered once daily. NX-5948 will be given in continuous 28-day cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate without partial response with lymphocytosis (PR-L) as determined by an Independent Review Committee (IRC)Time frame: Up to approximately 5 years

Locations

47 sites in 5 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Phoenix, Arizona · Recruiting

  • City of Hope

    Duarte, California · Recruiting

  • University of California, Irvine

    Irvine, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Scripps Health

    San Diego, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • Colorado Blood Institute

    Denver, Colorado · Recruiting

  • University of Miami

    Coral Gables, Florida · Recruiting

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • The University of Chicago

    Chicago, Illinois · Recruiting

  • Fort Wayne Oncology and Hematology

    Fort Wayne, Indiana · Recruiting

  • Hematology Oncology of Indiana

    Indianapolis, Indiana · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • Maryland Oncology Hematology

    Silver Spring, Maryland · Recruiting

  • Karmanos Cancer Center

    Detroit, Michigan · Recruiting

  • Duke University

    Durham, North Carolina · Recruiting

  • Novant Health Cancer Institute

    Winston-Salem, North Carolina · Recruiting

  • University of Cincinnati

    Cincinnati, Ohio · Recruiting

  • The Cleveland Clinic Foundation

    Cleveland, Ohio · Recruiting

  • The Ohio State University

    Columbus, Ohio · Recruiting

  • Oncology Hematology Care

    Fairfield, Ohio · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Texas Oncology - Center South

    Austin, Texas · Recruiting

  • The University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

  • Oncology & Hematology Associates of Southwest VA

    Blacksburg, Virginia · Recruiting

  • University of Virginia Medical Center

    Charlottesville, Virginia · Recruiting

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia · Recruiting

  • Virginia Oncology Associates

    Norfolk, Virginia · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • The Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • CHU de Nantes

    Nantes, France · Recruiting

  • Azienda Ospedaliero-Universitaria di Alessandria SS. Antonio e Biagio e Cesare Arrigo

    Alessandria, Italy · Recruiting

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola

    Bologna, Italy · Recruiting

  • ASST degli Spedali Civili di Brescia

    Brescia, Italy · Recruiting

  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori

    Meldola (FC), Italy · Recruiting

  • Ospedale San Raffaele S.r.l.

    Milan, Italy · Recruiting

  • AUSL della Romagna UO Ematologia

    Ravenna, Italy · Recruiting

  • Pratia Hematologia Sp. z o.o.

    Katowice, Poland · Recruiting

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.